CARLOS MANUEL
PANIZO SANTOS
Clínica Universitaria de Navarra
Pamplona, EspañaPublikationen in Zusammenarbeit mit Forschern von Clínica Universitaria de Navarra (51)
2021
-
Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients
Annals of Hematology, Vol. 100, Núm. 4, pp. 1023-1029
2020
-
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression
British Journal of Haematology, Vol. 189, Núm. 6, pp. 1064-1073
-
RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group
Annals of Hematology, Vol. 99, Núm. 4, pp. 799-808
2019
2018
-
A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies
Leukemia and Lymphoma, Vol. 59, Núm. 12, pp. 2888-2895
-
Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia
Immunotherapy, Vol. 10, Núm. 6, pp. 491-499
-
Update on posttransplant lymphoproliferative disease
Current Opinion in Nephrology and Hypertension, Vol. 27, Núm. 6, pp. 440-444
2017
-
Common variable immunodeficiency-associated granulomatous and lymphocytic interstitial lung disease successfully treated with a combination regimen of rituximab and azathioprine
Medicina Clinica, Vol. 149, Núm. 7, pp. 312-313
-
Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma
Blood
2016
-
Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity
Immunologic Research, Vol. 64, Núm. 2, pp. 548-557
-
Obinutuzumab in follicular lymphoma
Drugs of Today, Vol. 52, Núm. 12, pp. 643-651
2015
-
Antidesmocollin 1 autoantibody negative subcorneal pustular dermatosis-type IgA pemphigus associated with multiple myeloma
British Journal of Dermatology
2014
-
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: Results of a prospective, multicenter, phase II clinical trial
Haematologica
-
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: Results of a prospective, multicenter, phase II clinical trial
Haematologica, Vol. 99, Núm. 3, pp. 505-510
-
Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: A retrospective study of the Spanish experience
Annals of Hematology, Vol. 93, Núm. 9, pp. 1551-1558
-
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial
The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111
-
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: A phase II GELTAMO trial
British Journal of Haematology, Vol. 167, Núm. 3, pp. 327-336
2013
2012
-
Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain
Leukemia Research, Vol. 36, Núm. 6, pp. 709-714
2010
-
Anemia ferropénica: Estrategias dietéticas para su prevención
Actividad Dietetica, Vol. 14, Núm. 2, pp. 67-71